Michelle Eugeni

651 total citations
10 papers, 456 citations indexed

About

Michelle Eugeni is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Michelle Eugeni has authored 10 papers receiving a total of 456 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Epidemiology. Recurrent topics in Michelle Eugeni's work include Nanoparticle-Based Drug Delivery (2 papers), Cancer Research and Treatments (2 papers) and Neuroendocrine Tumor Research Advances (2 papers). Michelle Eugeni is often cited by papers focused on Nanoparticle-Based Drug Delivery (2 papers), Cancer Research and Treatments (2 papers) and Neuroendocrine Tumor Research Advances (2 papers). Michelle Eugeni collaborates with scholars based in United States, China and Hong Kong. Michelle Eugeni's co-authors include Steven K. Libutti, Geoffrey Seidel, Yvonne Shutack, Nadira Yuldasheva, Peter L. Choyke, T. Khanh, H. Richard Alexander, Shivaani Kummar, James F. Pingpank and James H. Doroshow and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Surgery.

In The Last Decade

Michelle Eugeni

10 papers receiving 443 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michelle Eugeni United States 6 182 157 120 102 91 10 456
Miguel Pérez-Bacete Spain 8 191 1.0× 123 0.8× 63 0.5× 30 0.3× 86 0.9× 15 535
Nancy Paz United States 9 201 1.1× 226 1.4× 50 0.4× 67 0.7× 149 1.6× 21 539
K. Beroukas Greece 6 135 0.7× 134 0.9× 49 0.4× 84 0.8× 91 1.0× 12 533
Shan M. Chin United States 7 249 1.4× 341 2.2× 43 0.4× 148 1.5× 110 1.2× 13 649
Trevor Do Canada 8 168 0.9× 237 1.5× 32 0.3× 201 2.0× 129 1.4× 11 475
H. I. Robins United States 11 235 1.3× 126 0.8× 36 0.3× 125 1.2× 88 1.0× 20 575
Hanxing Tong China 13 171 0.9× 118 0.8× 56 0.5× 87 0.9× 185 2.0× 56 675
Dennis Doleschel Germany 11 148 0.8× 169 1.1× 85 0.7× 49 0.5× 257 2.8× 17 678
E T Verghese United Kingdom 6 186 1.0× 110 0.7× 28 0.2× 147 1.4× 50 0.5× 6 429
Shundong Ji China 13 227 1.2× 122 0.8× 50 0.4× 48 0.5× 47 0.5× 35 500

Countries citing papers authored by Michelle Eugeni

Since Specialization
Citations

This map shows the geographic impact of Michelle Eugeni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Eugeni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Eugeni more than expected).

Fields of papers citing papers by Michelle Eugeni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Eugeni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Eugeni. The network helps show where Michelle Eugeni may publish in the future.

Co-authorship network of co-authors of Michelle Eugeni

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Eugeni. A scholar is included among the top collaborators of Michelle Eugeni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Eugeni. Michelle Eugeni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Speranza, Giovanna, Larry Anderson, Alice P. Chen, et al.. (2017). First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile. Investigational New Drugs. 36(2). 230–239. 31 indexed citations
2.
Khanh, T., Giovanna Speranza, Rachel Bishop, et al.. (2015). Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. Investigational New Drugs. 33(3). 720–728. 105 indexed citations
3.
Khanh, T., Liang Cao, Zhigang Kang, et al.. (2015). A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 14(3). 154–161. 22 indexed citations
4.
Jeong, Woondong, Sook Ryun Park, Annamaria Rapisarda, et al.. (2013). Abstract 2416: Weekly EZN-2208 (pegylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.. Cancer Research. 73(8_Supplement). 2416–2416. 1 indexed citations
5.
Wood, Bradford J., Ronnie T. P. Poon, Julia K. Locklin, et al.. (2011). Phase I Study of Heat-Deployed Liposomal Doxorubicin during Radiofrequency Ablation for Hepatic Malignancies. Journal of Vascular and Interventional Radiology. 23(2). 248–255.e7. 101 indexed citations
6.
Blansfield, Joseph, Shane Y. Morita, Peter L. Choyke, et al.. (2007). Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs). Surgery. 142(6). 814–818.e2. 172 indexed citations
7.
Libutti, S. K., Giulio F. Paciotti, William E. Gannon, et al.. (2007). Preliminary results of a phase I clinical trial of CYT-6091: A pegylated colloidal gold-TNF nanomedicine. Journal of Clinical Oncology. 25(18_suppl). 3603–3603. 15 indexed citations
8.
Wood, Bradford J., Ronnie T.P. Poon, Ziv Neeman, et al.. (2007). Phase I dose escalation and PK study of thermally sensitive liposomes containing doxorubicin given during radiofrequency ablation (RFA) in patients with non-resectable primary and metastatic liver cancer. Journal of Clinical Oncology. 25(18_suppl). 15010–15010. 3 indexed citations
9.
Wood, Bradford J., Ziv Neeman, Michelle Eugeni, et al.. (2007). Phase I study of thermally sensitive liposomes containing doxorubicin (ThermoDox) given during radiofrequency ablation (RFA) in patients with unresectable hepatic malignancies. 4 indexed citations
10.
Camphausen, Kevin, Martha Quezado, Deborah E. Citrin, et al.. (2007). A pilot study of local injection of TNFerade biologic in addition to neo-adjuvant chemoradiation for the treatment of primary and recurrent rectal cancer. Journal of Clinical Oncology. 25(18_suppl). 14585–14585. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miguel Pérez-Bacete Breakdown of academic impact, for papers by Nancy Paz Breakdown of academic impact, for papers by K. Beroukas Breakdown of academic impact, for papers by Shan M. Chin Breakdown of academic impact, for papers by Trevor Do Breakdown of academic impact, for papers by H. I. Robins Breakdown of academic impact, for papers by Hanxing Tong Breakdown of academic impact, for papers by Dennis Doleschel Breakdown of academic impact, for papers by E T Verghese Breakdown of academic impact, for papers by Shundong Ji
Rankless by CCL
2026